Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
3,854,053
-
Share change
-
+225,340
-
Total reported value
-
$15,775,696
-
Price per share
-
$4.16
-
Number of holders
-
30
-
Value change
-
+$867,220
-
Number of buys
-
12
-
Number of sells
-
9
Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q4 2025
As of 31 Dec 2025,
GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,854,053 shares.
The largest 10 holders included
VANGUARD GROUP INC, Geneos Wealth Management Inc., Sovran Advisors, LLC, RETIREMENT GUYS FORMULA LLC, Cambridge Investment Research Advisors, Inc., Fortis Capital Advisors, LLC, Belpointe Asset Management LLC, GSA CAPITAL PARTNERS LLP, Traynor Capital Management, Inc., and HighTower Advisors, LLC.
This page lists
30
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.